473 related articles for article (PubMed ID: 12620264)
1. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid.
Mazzi G; Raineri A; Zanolli FA; Da Ponte C; De Roia D; Santarossa L; Guerra R; Orazi BM
Transfus Apher Sci; 2003 Feb; 28(1):13-8. PubMed ID: 12620264
[TBL] [Abstract][Full Text] [Related]
2. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
Turner MS; Sutton D; Sauder DN
J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
4. Plasmapheresis therapy of pemphigus and bullous pemphigoid.
Roujeau JC
Semin Dermatol; 1988 Sep; 7(3):195-200. PubMed ID: 3153444
[TBL] [Abstract][Full Text] [Related]
5. Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid.
Yamada H; Yaguchi H; Takamori K; Ogawa H
Ther Apher; 1997 May; 1(2):178-82. PubMed ID: 10225767
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.
Schmidt E; Seitz CS; Benoit S; Bröcker EB; Goebeler M
Br J Dermatol; 2007 Feb; 156(2):352-6. PubMed ID: 17223877
[TBL] [Abstract][Full Text] [Related]
7. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
8. Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
Budimir J; Mihić LL; Situm M; Bulat V; Persić S; Tomljanović-Veselski M
Acta Clin Croat; 2008 Mar; 47(1):13-8. PubMed ID: 18714642
[TBL] [Abstract][Full Text] [Related]
9. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.
Marazza G; Pham HC; Schärer L; Pedrazzetti PP; Hunziker T; Trüeb RM; Hohl D; Itin P; Lautenschlager S; Naldi L; Borradori L;
Br J Dermatol; 2009 Oct; 161(4):861-8. PubMed ID: 19566661
[TBL] [Abstract][Full Text] [Related]
10. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
[TBL] [Abstract][Full Text] [Related]
11. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid.
Bhol KC; Rojas AI; Khan IU; Ahmed AR
Cytokine; 2000 Jul; 12(7):1076-83. PubMed ID: 10880254
[TBL] [Abstract][Full Text] [Related]
12. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
Ahmed AR
Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
15. [Plasma exchange therapy in pemphigus vulgaris and bullous pemphigoid--our clinical experiences and the role of bullous pemphigoid antibody in blister formation].
Watanabe S
Nihon Hifuka Gakkai Zasshi; 1983 Aug; 93(9):953-64. PubMed ID: 6363766
[No Abstract] [Full Text] [Related]
16. [Plasmapheresis in the treatment of pemphigus].
Blaszczyk M; Chorzelski T; Daszynski J; Jabłońska S; Beutner EH
Z Hautkr; 1985 Aug; 60(15):1175-82. PubMed ID: 4049988
[TBL] [Abstract][Full Text] [Related]
17. [Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids].
Boughrara Z; Ingen-Housz-Oro S; Legrand P; Duong TA; Roujeau JC
Ann Dermatol Venereol; 2010 May; 137(5):345-51. PubMed ID: 20470914
[TBL] [Abstract][Full Text] [Related]
18. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
Mahajan VK; Sharma NL; Sharma RC; Garg G
Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
20. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
